Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4

Vaccine

Volumn 32, Issue 25, 2014, Pages 3010-3018

  Gromowski, Gregory D ^a   Firestone, Cai Yen ^a   Hanson, Christopher T ^a   Whitehead, Stephen S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chimeric virus; Japanese encephalitis virus; Live attenuated vaccine

Indexed keywords

DENGUE VACCINE; JAPANESE ENCEPHALITIS VACCINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 4; E GENE; EPIDEMIC ENCEPHALITIS; FEMALE; GENE MUTATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS; LIMIT OF DETECTION; MOLECULAR CLONING; MOUSE; NONHUMAN; NONSTRUCTURAL PROTEIN 3 GENE; NONSTRUCTURAL PROTEIN 4B GENE; PRIORITY JOURNAL; SEROCONVERSION; ST LOUIS FLAVIVIRUS; STRUCTURAL GENE; SURVIVAL TIME; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS; WILD TYPE;

CHIMERIC VIRUS; JAPANESE ENCEPHALITIS VIRUS; LIVE-ATTENUATED VACCINE;

ANIMALS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; FEMALE; JAPANESE ENCEPHALITIS VACCINES; MEMBRANE GLYCOPROTEINS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; RNA HELICASES; SERINE ENDOPEPTIDASES; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84899953355     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.062     Document Type: Article

References (48)

1. Lindenbach B.D., Rice C.M. Molecular biology of flaviviruses. Adv Virus Res 2003, 59:23-61.
2. Pierson T.C., Fremont D.H., Kuhn R.J., Diamond M.S. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell host & microbe 2008, 4:229-238.
3. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 2000, 18(Suppl 2):26-32.
4. Solomon T., Ni H., Beasley D.W., Ekkelenkamp M., Cardosa M.J., Barrett A.D. Origin and evolution of Japanese encephalitis virus in southeast Asia. Journal of virology 2003, 77:3091-3098.
5. Liu X., Yu Y., Li M., Liang G., Wang H., Jia L., et al. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China. Vaccine 2011, 29:2127-2130.
6. Beasley D.W., Li L., Suderman M.T., Guirakhoo F., Trent D.W., Monath T.P., et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 2004, 22:3722-3726.
7. Kurane I., Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 2000, 18(Suppl 2):33-35.
8. Beasley D.W., Lewthwaite P., Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 2008, 8(1):95-106.
9. Tsarev S.A., Sanders M.L., Vaughn D.W., Innis B.L. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 2000, 18(Suppl 2):36-43.
10. Campbell G.L., Hills S.L., Fischer M., Jacobson J.A., Hoke C.H., Hombach J.M., et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bulletin of the World Health Organization 2011, 89:766-774. 74A-74E.
11. Solomon T., Vaughn D.W. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol 2002, 267:171-194.
12. van den Hurk A.F., Ritchie S.A., Mackenzie J.S. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009, 54:17-35.
13. Halstead S.B., Thomas S.J. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines 2011, 10(3):355-364.
14. Appaiahgari M.B., Vrati S. Clinical development of IMOJEV (R)-a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther 2012, 12(9):1251-1263.
15. McArthur M.A., Holbrook M.R. Japanese Encephalitis Vaccines. J Bioterror Biodef 2011, S1:2.
16. Eckels K.H., Yu Y.X., Dubois D.R., Marchette N.J., Trent D.W., Johnson A.J. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988, 6:513-518.
17. Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 2010, 28(21):3635-3641.
18. Gould E.A., Solomon T. Pathogenic flaviviruses. Lancet 2008, 371(9611):500-509.
19. Coller B.A., Clements D.E. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011, 23(3):391-398.
20. Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587-619.
21. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Elwood D., Larsson C.J., Lindow J.C., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. The Journal of infectious diseases 2013, 207:957-965.
22. Pletnev A.G., Bray M., Huggins J., Lai C.J. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10532-10536.
23. Blaney J.E., Speicher J., Hanson C.T., Sathe N.S., Whitehead S.S., Murphy B.R., et al. Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys. Vaccine 2008, 26:4150-4159.
24. Pletnev A.G., Putnak R., Speicher J., Wagar E.J., Vaughn D.W. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:3036-3041.
25. Whitehead S.S., Hanley K.A., Blaney J.E., Gilmore L.E., Elkins W.R., Murphy B.R. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003, 21:4307-4316.
26. Gulati B.R., Singha H., Singh B.K., Virmani N., Kumar S., Singh R.K. Isolation and genetic characterization of Japanese encephalitis virus from equines in India. Journal of veterinary science 2012, 13:111-118.
27. Uchil P.D., Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. Am J Trop Med Hyg 2001, 65(3):242-251.
28. Song B.H., Yun G.N., Kim J.K., Yun S.I., Lee Y.M. Biological and genetic properties of SA(1)(4)-14-2, a live-attenuated Japanese encephalitis vaccine that is currently available for humans. Journal of microbiology 2012, 50:698-706.
29. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. The American journal of tropical medicine and hygiene 2001, 65:405-413.
30. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hygiene 1938, 27(3):493-497.
31. Pierson T.C., Sanchez M.D., Puffer B.A., Ahmed A.A., Geiss B.J., Valentine L.E., et al. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 2006, 346:53-65.
32. Pierson T.C., Xu Q., Nelson S., Oliphant T., Nybakken G.E., Fremont D.H., et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell host & microbe 2007, 1:135-145.
33. Pletnev A.G., Men R. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. Proc Natl Acad Sci USA 1998, 95(4):1746-1751.
34. Chambers T.J., Nestorowicz A., Mason P.W., Rice C.M. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. Journal of virology 1999, 73:3095-3101.
35. Liu Z.Y., Li X.F., Jiang T., Deng Y.Q., Zhao H., Wang H.J., et al. A novel cis-acting element within the capsid-coding region enhances flavivirus vRNA replication by regulating genome cyclization. Journal of virology 2013.
36. Friebe P., Pena J., Pohl M.O., Harris E. Composition of the sequence downstream of the dengue virus 5' cyclization sequence (dCS) affects viral RNA replication. Virology 2012, 422:346-356.
37. Samsa M.M., Mondotte J.A., Caramelo J.J., Gamarnik A.V. Uncoupling cis-Acting RNA elements from coding sequences revealed a requirement of the N-terminal region of dengue virus capsid protein in virus particle formation. Journal of virology 2012, 86:1046-1058.
38. Khromykh A.A., Westaway E.G. RNA binding properties of core protein of the flavivirus Kunjin. Arch Virol 1996, 141(3-4):685-699.
39. Pong W.L., Huang Z.S., Teoh P.G., Wang C.C., Wu H.N. RNA binding property and RNA chaperone activity of dengue virus core protein and other viral RNA-interacting proteins. FEBS letters 2011, 585:2575-2581.
40. Stocks C.E., Lobigs M. Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM. J Virol 1998, 72(3):2141-2149.
41. Lobigs M., Lee E. Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes. J Virol 2004, 78(1):178-186.
42. Lee E., Stocks C.E., Amberg S.M., Rice C.M., Lobigs M. Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage in vitro is lethal for virus production. Journal of virology 2000, 74:24-32.
43. Amberg S.M., Rice C.M. Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing. J Virol 1999, 73(10):8083-8094.
44. Blaney J.E., Manipon G.G., Firestone C.Y., Johnson D.H., Hanson C.T., Murphy B.R., et al. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 2003, 21:4317-4327.
45. Hanley K.A., Manlucu L.R., Gilmore L.E., Blaney J.E., Hanson C.T., Murphy B.R., et al. A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology 2003, 312:222-232.
46. Men R., Bray M., Clark D., Chanock R.M., Lai C.J. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. Journal of virology 1996, 70:3930-3937.
47. Luca V.C., AbiMansour J., Nelson C.A., Fremont D.H. Crystal structure of the Japanese encephalitis virus envelope protein. Journal of virology 2012, 86:2337-2346.
48. Fritz R., Stiasny K., Heinz F.X. Identification of specific histidines as pH sensors in flavivirus membrane fusion. J Cell Biol 2008, 183(2):353-361.